MedImmune Overview
- Year Founded
-
1988
- Status
-
Acquired/Merged
- Employees
-
3,000
- Latest Deal Type
-
M&A
- Financing Rounds
-
5
- Investments
-
21
MedImmune General Information
Description
Developer of drugs for prevention and treatment of infectious disease, autoimmune diseases and cancer. The company undertakes the research and development, manufacture and marketing of biologics to address some of the major medical needs in the healthcare industry.
Contact Information
Website
www.medimmune.comCorporate Office
- One MedImmune Way
- Gaithersburg, MD 20878
- United States
Corporate Office
- One MedImmune Way
- Gaithersburg, MD 20878
- United States
MedImmune Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
MedImmune Comparisons
Industry
Financing
Details
MedImmune Competitors (59)
One of MedImmune’s 59 competitors is Samsung Bioepis, a Corporate Backed or Acquired company based in Incheon, South Korea.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Samsung Bioepis | Corporate Backed or Acquired | Incheon, South Korea | ||||
| Incyte | Formerly VC-backed | Wilmington, DE | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Biocon Biologics | Formerly PE-Backed | Bengaluru, India | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China |
MedImmune Patents
MedImmune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026229570-A1 | Treatment with anti-tslp antibody | Pending | 01-May-2025 | ||
| WO-2026093970-A1 | Combination dosage regimens of amylin receptor agonists and glp-1 receptor agonists | Pending | 01-Nov-2024 | ||
| US-20260131017-A1 | Cd22 antibody and drug conjugates and uses thereof | Pending | 11-Oct-2024 | ||
| WO-2026078620-A1 | Cd22 antibody and drug conjugates and uses thereof | Pending | 11-Oct-2024 | ||
| WO-2026058194-A1 | Polypeptide dosage regimens | Pending | 12-Sep-2024 | A61K38/22 |
MedImmune Signals
MedImmune Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
MedImmune Investments & Acquisitions (21)
MedImmune’s most recent deal was a Early Stage VC with Corvidia Therapeutics for . The deal was made on 25-Apr-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Corvidia Therapeutics | 25-Apr-2018 | Early Stage VC | Biotechnology | ||
| Corvidia Therapeutics | 17-Feb-2016 | Early Stage VC | Biotechnology | ||
| Inovio Pharma (Rights to INO-3112 immunotherapy drug) | 10-Oct-2015 | Corporate Asset Purchase | Buildings and Property | ||
| Definiens | 25-Nov-2014 | Merger/Acquisition | Other Healthcare Technology Systems | ||
| Allozyne | 01-Jan-2014 | Merger/Acquisition | Pharmaceuticals |
MedImmune Exits (11)
MedImmune’s most recent exit was on 25-Apr-2018 from Corvidia Therapeutics. The exit was categorized as with 10 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Corvidia Therapeutics | 25-Apr-2018 | Completed |
|
||
| Corvidia Therapeutics | 17-Feb-2016 | Completed |
|
||
| Faeth Therapeutics | 01-May-2002 | Completed |
|
||
| Applied Molecular Evolution | 15-Jun-2000 | Completed |
|
||
| Applied Molecular Evolution | 11-Sep-1997 | Later Stage VC | Completed |
|
MedImmune Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| MedImmune Ventures | Gaithersburg, MD | 2002 |
MedImmune FAQs
-
When was MedImmune founded?
MedImmune was founded in 1988.
-
Where is MedImmune headquartered?
MedImmune is headquartered in Gaithersburg, MD.
-
What is the size of MedImmune?
MedImmune has 3,000 total employees.
-
What industry is MedImmune in?
MedImmune’s primary industry is Biotechnology.
-
Is MedImmune a private or public company?
MedImmune is a Private company.
-
What is the current valuation of MedImmune?
The current valuation of MedImmune is .
-
What is MedImmune’s current revenue?
The current revenue for MedImmune is .
-
Who are MedImmune’s investors?
Global Emerging Markets, HealthCare Ventures, Patricia Industries, and Rho Acceleration have invested in MedImmune.
-
Who are MedImmune’s competitors?
Samsung Bioepis, Incyte, Merck & Co., Biocon Biologics, and BeOne Medicines are some of the 59 competitors of MedImmune.
-
When was MedImmune acquired?
MedImmune was acquired on 19-Jun-2007.
-
Who acquired MedImmune?
MedImmune was acquired by AstraZeneca.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process